恒瑞医药:子公司卓托奇拜单抗注射液上市申请获受理

财中社
Sep 03

9月3日,恒瑞医药(600276/01276)发布公告,子公司广东恒瑞医药有限公司收到国家药监局下发的《受理通知书》,公司的卓托奇拜单抗注射液药品上市许可申请获国家药监局受理。  卓托奇拜单抗注射液用于治疗外用药控制不佳或不适合外用药治疗的成人中重度特应性皮炎。  公告提到,SHR-1819 注射液是公司自主研发的一种靶向人IL-4Rα的重组人源化单克隆抗体,能够同时阻断IL-4和IL-13的信号...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10